GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
issued a press release announcing its preliminary financial
results for the fiscal quarter ended March 31, 2017. A copy of
the press release is attached hereto as Exhibit 99.1.
99.1 attached hereto, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of that section, nor shall it
be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or under the Securities
Exchange Act of 1934, as amended, regardless of any general
incorporation language in any such filing, unless the Company
expressly sets forth in such filing that such information is to
be considered filed or incorporated by reference therein.
|
(d)
|
The following exhibit is furnished with this Current
Report: |
|
99.1
|
Press release dated April 20, 2017.
|
About GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK)
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel. GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Recent Trading Information
GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) closed its last trading session down -0.01 at 12.96 with 281,683 shares trading hands.